In a ground-breaking move that promises to transform patient care across the nation, Agilus Diagnostics has announced the launch of its Pharmacogenomics Testing Service. This innovative service empowers healthcare providers and patients with vital insights into how individual genetic profiles influence medication effectiveness and safety, paving the way for a more personalised approach to treatment.

Commenting on the initiative, Dr Anand K, Managing Director & CEO of Agilus Diagnostics said, “With the increasing prevalence of diseases such as cancer, cardiovascular disorders and diabetes, our new service harnesses state-of-the-art genome sequencing technologies to provide tailored treatment strategies that can significantly enhance patient outcomes.”

As we continue to explore the genetic underpinnings of psychiatric disorders and treatment responses, pharmacogenomics stands at the forefront of a new era in psychiatry. This approach holds the promise of not only better patient outcomes but also a more nuanced and individualized understanding of mental health. With its ability to guide medication selection and dosing, pharmacogenomics is paving the way for a future in which psychiatric care is more effective, efficient, and personalised than ever before.

Agilus’ comprehensive pharmacogenomics panel based on whole exome sequencing covers 59 PGx genes and 194 drugs. It also covers 32 genes associated with clinical annotations & dosing guidelines. The reporting is based as per the standard dosing guidelines, which incorporates 191 CPIC, 108 DPWG and many others. The drug genomics panel includes 17 speciality, like cancer, cardiovascular disorders, depression, neurology, gastroenterology, paediatrics, endocrinology and immunosuppressant medications etc.